O
4.50
0.12 (2.76%)
| Previous Close | 4.38 |
| Open | 4.26 |
| Volume | 96,268 |
| Avg. Volume (3M) | 862,771 |
| Market Cap | 3,351,905 |
| Price / Sales | 1.71 |
| 52 Weeks Range | |
| Earnings Date | 20 May 2024 |
| Operating Margin (TTM) | -300.33% |
| Diluted EPS (TTM) | -109.20 |
| Current Ratio (MRQ) | 0.100 |
| Operating Cash Flow (TTM) | -15.78 M |
| Levered Free Cash Flow (TTM) | -6.06 M |
| Return on Assets (TTM) | -21.85% |
| Return on Equity (TTM) | -1,758.48% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Onconetix, Inc. | - | - |
Stockmoo Score
0.5
| Analyst Consensus | 0.0 |
| Insider Activity | 2.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 57.64% |
| % Held by Institutions | 1.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Zurcher Kantonalbank (Zurich Cantonalbank) | 30 Jun 2024 | 7,652 |
| Bahl & Gaynor Inc | 30 Jun 2024 | 868 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MEIER THOMAS | 3.36 | - | 3,318 | 11,132 |
| RAMDEEN TIMOTHY R. | 3.36 | - | 3,318 | 11,132 |
| SAPIRSTEIN JAMES | 3.36 | - | 3,318 | 11,132 |
| SINGH AJIT | 3.36 | - | 3,318 | 11,132 |
| TARSH SIMON | 3.36 | - | 3,318 | 11,132 |
| Aggregate Net Quantity | 16,590 | |||
| Aggregate Net Value ($) | 55,659 | |||
| Aggregate Avg. Buy ($) | 3.36 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MEIER THOMAS | Director | 26 Sep 2024 | Acquired (+) | 3,318 | 3.36 | 11,132 |
| RAMDEEN TIMOTHY R. | Director | 26 Sep 2024 | Acquired (+) | 3,318 | 3.36 | 11,132 |
| SAPIRSTEIN JAMES | Director | 26 Sep 2024 | Acquired (+) | 3,318 | 3.36 | 11,132 |
| SINGH AJIT | Director | 26 Sep 2024 | Acquired (+) | 3,318 | 3.36 | 11,132 |
| TARSH SIMON | Director | 26 Sep 2024 | Acquired (+) | 3,318 | 3.36 | 11,132 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |